This site is intended only for all Healthcare Professionals residing in South Africa

Search

Menu

Close

Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer medical information

Menu

Close

Rheumatoid arthritis (RA) Rheumatoid arthritis (RA) Dosage and Administration Dose Adjustments and Drug Interactions Efficacy Mechanism of Action Prescribing Information Safety Special Populations and Contraindications Special Warnings and Precautions Psoriatic arthritis (PsA) Psoriatic arthritis (PsA) Dosage and Administration Dose Adjustments and Drug Interactions Efficacy Mechanism of Action Prescribing Information Safety Special Populations and Contraindications Special Warnings and Precautions Ulcerative colitis (UC) Ulcerative colitis (UC) Dosage and Administration Dose Adjustments and Drug Interactions Efficacy Mechanism of Action Prescribing Information Safety Special Populations and Contraindications Special Warnings and Precautions
Mechanism of ActionXELJANZ® (tofacitinib) is a pharmacological class of small molecules with a simultaneous effect on multiple mediators of inflammation and an oral formulation called Janus Kinase (JAK) Inhibitors1

The oral route of administration, the short half-life, and the fast onset of action are key advantages of JAK inhibitors.3 The development and application of JAK inhibitors are a breakthrough in the treatment of autoimmune diseases.5 JAK inhibitors have the potential to deliver prolonged efficacy and clinically meaningful patient benefits.6

ReferencesFavalli EG, Matucci-Cerinic M, Szekanecz Z. The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis. Autoimmunity Reviews 2020;19(1):102421.Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003;3(11):900-11.Ferrante M, Sabino J. Efficacy of JAK inhibitors in Ulcerative Colitis. Journal of Crohn’s and Colitis 2020;14(2):S737-S745.Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib–an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2016;34(2):318-328.Chen M, Dai S. A novel treatment for psoriatic arthritis: Janus kinase inhibitors. Chinese Medical Journal 2020;133(8):959–967.Danese S, Grisham M, Hodge J, et al. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol 2016;310(3):G155-62
PP-XEL-ZAF-0083

Copyright ©2024 Pfizer South Africa All rights reserved.

  • The information contained herein is provided for educational purposes only and is not intended to constitute medical advice or replace discussions with a Healthcare Professional. All decisions regarding patient care must be made with a Healthcare Professional, considering the unique characteristics of the patient.
  • While every effort is made to update the information regularly and to offer the most current, correct and clearly expressed information possible, Pfizer cannot be held responsible for any inaccuracy, errors, omissions or misinterpretations.
  • Pfizer, its officers and/or its employees do not accept or take any responsibility whatsoever for any loss, whether direct, indirect or consequential, which may arise from reliance on information contained on these pages and actions resulting therefrom. Any liability that would or could arise as a result of the contents of these pages is hereby excluded to the fullest extent allowed by law.
  • No warranty is given that any files, downloads or applications available via this web site are free of viruses which have the ability to corrupt your system.
  • Any and all information is subject to change without notice.
  • The information provided in this site is intended only for appropriate Healthcare Professionals residing in South Africa.

 

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This site is intended only for all Healthcare Professionals residing in South Africa. If you are a member of the public wishing to access information on a specific medicine, please visit www.pfizer.co.za.

 

This website is brought to you by Pfizer South Africa 

Pfizer Laboratories (Pty) Ltd. Company Reg. No. 1954/000781/07. Building 2, 1st Floor, Maxwell Office Park, Magwa Crescent, Waterfall City, Midrand, Johannesburg, South Africa. Tel. No: 0860 PFIZER (734937).

 

Copyright © 2024. Pfizer Laboratories (Pty) Ltd. All rights reserved

PP-UNP-ZAF-0309
For South Africa Healthcare Professionals *


These pages are not intended for patients or for members of the general public. The healthcare professional webpages contain promotional content.

I confirm that I am a healthcare professional residing in South Africa. If you select 'No', you will be redirected to Pfizer.co.za where you will be able to access reference information on Pfizer's prescription medicines.
 

Yes No
You are now leaving the PfizerPro South Africa website
You are leaving the South Africa HCP Portal website and being directed to a new website

This website is not controlled by South Africa HCP portal or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable
You are now leaving PfizerPro You are now leaving PfizerPro and will be directed to our provider to complete your registration. Any personal information that you may find prepopulated from your PfizerPro profile, or you may provide, will be governed by Privacy Policy. Your data will not be used for any other purpose.

PP-UNP-ZAF-0303